Shveta Jain, MD
Pain Medicine · Fullerton, CANPI 1598024226
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $349,749 of the $350,795 with a category attached, or 99.7%. Masimo Corporation accounts for 99.9% of it on its own, with 5 other manufacturers making up the rest. Among pain medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $2126.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Masimo Corporation$350K
- Forte Bio-pharma LLC$185
- Scilex Pharmaceuticals Inc.$42
- Biodelivery Sciences International, Inc.$39
- Boston Scientific$28
- Pfizer$22
What the payments were for
- Speaking & faculty fees$349,749100%
- Food & beverage$1,0460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Masimo Corporation | 149 | $350,479 |
| Forte Bio-pharma LLC | 9 | $185 |
| Scilex Pharmaceuticals Inc. | 2 | $42 |
| Biodelivery Sciences International, Inc. | 3 | $39 |
| Boston Scientific | 1 | $28 |
| Pfizer | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Patient SafetyNet System$284,154
- EMMA and ISA$65,596
How this compares
$350,795 in reported general payments places this provider in the 95th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine | 25 | $3,627 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 165 | $2,897 |
| Naloxone Hcl | 53 | $2,872 |
| Gabapentin | 201 | $1,780 |
| Diclofenac Sodium | 62 | $1,379 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 57 | $1,161 |
| Pregabalin | 53 | $1,061 |
| Celecoxib | 55 | $780 |
| Baclofen | 92 | $564 |
| Tizanidine Hcl | 33 | $418 |
| Duloxetine Hcl | 25 | $319 |
| Cyclobenzaprine Hcl | 54 | $317 |
| Amitriptyline Hcl | 37 | $230 |
| Methocarbamol | 29 | $226 |
| Tramadol Hcl | 44 | $159 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Fullerton
- Jason PopeSanta Rosa$2.1M
- Ramana NaiduLarkspur$1.4M
- Foead GeulaStudio City$1.3M
- Krishnan ChakravarthyTemecula$1.3M
- Kasra AmirdelfanWalnut Creek$783K
- Eric GrigsbyNapa$499K
- Jacqueline WeisbeinNapa$494K
- Gerald SacksSanta Monica$389K
- Samir ShethRoseville$356K
- Einar OttestadStanford$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.